StockVS

Synergy CHC Corp. (SNYR) Stock Analysis

Healthcare

Synergy CHC Corp.

$0.27

+$0.01 (+3.92%)

Last Updated: May 26, 2026

Price History

Analysis

Company Overview

Synergy CHC Corp. operates within the healthcare sector as a specialized entity focused on the medical distribution industry, specifically providing consumer health care, beauty, and lifestyle products across the United States, Canada, and the United Kingdom. The company's portfolio includes brain health nutritional supplements sold under the FOCUSfactor brand name, alongside a diverse range of lifestyle and wellness products and accessories such as tea, shakes, and lollipops. This business model serves a global consumer base with a relatively small operational footprint, employing 21 individuals to manage its distribution and product lines. The company's current market capitalization stands at $13.61M, while its trailing twelve-month revenue reaches $34.59M, indicating a micro-cap status that reflects a niche market position rather than broad-based industry dominance. These valuation figures suggest the company operates with limited capital resources compared to larger peers, which constrains its ability to rapidly expand market share or absorb significant economic shocks, positioning it as a small-scale player in the broader consumer health landscape.

Financial Health

Synergy CHC Corp. reported annual revenue of $34.59M and net income of $2.58M over the trailing twelve months, generating an EBITDA of $6.34M. The substantial gap between the $34.59M in revenue and the $2.58M in net income reveals a cost structure where operating expenses consume approximately 92.5% of top-line revenue, leaving a profit margin of 7.5%. The company generated negative free cash flow of $-7,820,155, which indicates a significant cash burn rate that limits financial flexibility and suggests that current capital expenditures or working capital requirements exceed operational cash generation. Despite the negative free cash flow, the firm maintains a cash balance of $1.01M, which serves as a limited liquidity buffer against its total debt load of $25.11M. The balance sheet appears highly leveraged given the debt level relative to available cash, although the debt-to-equity ratio is listed as N/A, preventing a precise leverage calculation. Liquidity is robust relative to immediate obligations, evidenced by a current ratio of 5.35, which indicates the company holds more than five times the current assets necessary to cover its short-term liabilities. Return on Assets stands at 23.6%, demonstrating efficient asset utilization in generating income, while Return on Equity is listed as N/A, likely due to the company's negative book value derived from a price-to-book ratio of -1.65.

Valuation Assessment

The trailing twelve-month P/E ratio is 4.32, while the forward P/E ratio is 3.90. The difference between these two metrics implies that the market expects earnings to decline or grow at a rate that adjusts the valuation multiple downward, as the forward multiple is lower than the trailing multiple. The price-to-book ratio is -1.65, which indicates that the market is valuing the company at a discount to its book value, a phenomenon often associated with firms that have accumulated significant liabilities or negative equity positions. Alternative valuation metrics include a price-to-sales ratio of 0.39 and an EV/EBITDA of 5.95, which suggest the company is valued on a low multiple of its sales and earnings before interest, taxes, depreciation, and amortization relative to its enterprise value. The stock's 52-week trading range spans from a low of $1.18 to a high of $4.08, meaning the current price sits at a level that must be compared against this specific historical volatility to determine relative positioning. With a beta of 1.27, the stock exhibits price volatility that is 27% higher than the broader market, indicating that the security is more sensitive to general market movements and economic cycles than a standard benchmark index.

Growth & Income

Revenue growth over the last year stands at 12.4%, whereas earnings growth declined by 90.6% year-over-year. This divergence implies that while top-line sales are expanding, profitability is deteriorating rapidly, suggesting that cost pressures or one-time charges are outpacing revenue gains. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that all earnings are retained within the business rather than distributed to shareholders. Consequently, the company reinvests its earnings into operations or growth initiatives rather than providing an income stream to investors. The overall growth and income profile is characterized by positive revenue expansion contrasted with sharply declining earnings and an absence of dividend distributions, reflecting a high-risk, high-volatility capital allocation strategy typical of small-cap micro-cap stocks.

Peer Comparison

Synergy CHC Corp. (SNYR) operates in the Medical Distribution industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Synergy CHC Corp. SNYR $3.95M N/A
McKesson Corporation MCK $90.68B 19.6
Cencora, Inc. COR $52.68B 20.8
Cardinal Health, Inc. CAH $46.93B 30.6

The Medical Distribution industry average P/E ratio is 23.3x. Synergy CHC Corp. trades at a P/E of N/A.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Synergy CHC Corp.

Synergy CHC Corp. provides consumer health care, beauty, and lifestyle products in the United States, Canada, Mexico, and internationally. It offers brain health nutritional supplements under the FOCUSfactor brand name; and lifestyle and wellness products and accessories, including tea, shakes, lollipops, supplements, apparel, and exercise accessories under the Flat Tummy brand name. The company also provides hand care products under the Hand MD brand name; Neuragen a homeopathic product; and UrgentRx, an over the counter drug. It sells its products through club, mass drug, and other retailers. The company was formerly known as Synergy Strips Corp. and changed its name to Synergy CHC Corp. in August 2015. The company was incorporated in 2010 and is based in Windham, Maine.

Visit website →

Key Statistics

Market Cap
$3.95M
P/E Ratio
N/A
52-Week High
$4.00
52-Week Low
$0.23
Avg Volume
1.67M
Beta
0.79

Data provided by Yahoo Finance via yfinance. Updated daily.

Company Info

Exchange
NASDAQ
Country
United States
Employees
28